2 reports of this reaction
2.3% of all PULSATILLA VULGARIS reports
#5 most reported adverse reaction
ANXIETY is the #5 most commonly reported adverse reaction for PULSATILLA VULGARIS. There are 2 FDA adverse event reports linking PULSATILLA VULGARIS to ANXIETY. This represents approximately 2.3% of all 86 adverse event reports for this drug.
Patients taking PULSATILLA VULGARIS who experience anxiety should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANXIETY is a less commonly reported adverse event for PULSATILLA VULGARIS, but still significant enough to appear in the safety profile.
In addition to anxiety, the following adverse reactions have been reported for PULSATILLA VULGARIS:
The following drugs have also been linked to anxiety in FDA adverse event reports:
ANXIETY has been reported as an adverse event in 2 FDA reports for PULSATILLA VULGARIS. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANXIETY accounts for approximately 2.3% of all adverse event reports for PULSATILLA VULGARIS, making it a notable side effect.
If you experience anxiety while taking PULSATILLA VULGARIS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.